Yazar "Havrdova, Eva Kubala" için listeleme
-
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder
Kunchok, Amy; Malpas, Charles; Nytrova, Petra; Havrdova, Eva Kubala; Alroughani, Raed; Terzi, Murat; Oreja-Guevara, Celia (Elsevier Sci Ltd, 2020)Background: Aquaporin-4-IgG positive (AQP4-IgG(+)) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG + NMOSD are typically measured by ... -
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Turkoglu, Recai (Bmj Publishing Group, 2019)Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. Methods We identified all patients with ... -
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Nguyen, Ai-Lan; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Kalincik, Tomas; van der Walt, Anneke; Granella, Franco (Elsevier Sci Ltd, 2019)Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RAMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and ... -
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Turkoglu, Recai (Sage Publications Ltd, 2020)Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and ...
